drugset / Trial / NCT01702194

TD-1211 IV/Oral Mass Balance Study

NCT01702194

Phase 1 Completed 10 enrolled Glycyx Therapeutics
Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine TD-1211 is processed by the body.

Timeline

Start
2012-11
Primary completion
2013-02
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject axelopran Small molecule Intravenous